A New Device to Monitor Heart Dysfunction in Childhood Cancer Survivors

Anthracyclines, a widely used class of chemotherapeutics, work in several ways to kill rapidly dividing cells, including those found in a tumor. While these drugs are commonly used to treat many types of adult and childhood cancer, they have a detrimental side effect – cardiotoxicity.

The cardiotoxicity of anthracyclines is dose-dependent; the more exposure patients have to the drug, the more serious risk they carry for heart-related problems. This can represent a unique challenge in children treated with anthracyclines, whose hearts are still developing.

Read More

Q&A With Kimberly Stegmaier, MD, on Pediatric Cancer Research

Kimberly Stegmaier, MD, co-director of the pediatric hematologic malignancy program and associate professor of pediatrics at Dana-Farber Cancer Institute and Boston Children’s Hospital, previews the areas of research that will be featured at the Advances in Pediatric Cancer Research meeting.

Read More